➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKesson
Merck
McKinsey
Express Scripts
Mallinckrodt

Last Updated: October 27, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR APALUTAMIDE

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for Apalutamide

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01946204 A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer Recruiting Aragon Pharmaceuticals, Inc. Phase 3 2013-10-01 The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate cancer.
NCT02257736 An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC Active, not recruiting Aragon Pharmaceuticals, Inc. Phase 3 2014-11-01 The purpose of this study is to compare the radiographic progression-free survival (rPFS) of apalutamide in combination with abiraterone acetate (AA) plus prednisone or prednisolone (AAP) and AAP in participants with chemotherapy-naive (participants who did not receive any chemotherapy [treatment of cancer using drugs]) metastatic castration-resistant prostate cancer (mCRPC) (cancer of prostate gland [gland that makes fluid that aids movement of sperm]).
NCT02489318 A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC Recruiting Aragon Pharmaceuticals, Inc. Phase 3 2015-11-01 The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.
NCT02578797 A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study Recruiting Aragon Pharmaceuticals, Inc. Phase 1 2015-12-01 The purpose of this study is to determine whether daily treatment with apalutamide affects the ventricular repolarization in participants with Castration-Resistant Prostate Cancer (CRPC)
NCT02772588 AASUR in High Risk Prostate Cancer Recruiting Janssen Pharmaceuticals Phase 2 2016-05-01 The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.
NCT02772588 AASUR in High Risk Prostate Cancer Recruiting University of Michigan Phase 2 2016-05-01 The purpose of this study is to determine whether anti-testosterone medications, when administered before, during, and after high-dose, precision radiation, will be effective in preventing the prostate cancer from returning.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Apalutamide

Condition Name

Condition Name for Apalutamide
Intervention Trials
Prostate Cancer 20
Prostatic Neoplasms 11
Prostate Adenocarcinoma 7
Stage IVA Prostate Cancer AJCC v8 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Apalutamide
Intervention Trials
Prostatic Neoplasms 57
Adenocarcinoma 13
Prostatic Neoplasms, Castration-Resistant 3
Carcinoma 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Apalutamide

Trials by Country

Trials by Country for Apalutamide
Location Trials
United States 151
Canada 28
Brazil 10
Spain 8
France 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Apalutamide
Location Trials
Texas 11
New York 11
California 10
Michigan 7
Massachusetts 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Apalutamide

Clinical Trial Phase

Clinical Trial Phase for Apalutamide
Clinical Trial Phase Trials
Phase 4 1
Phase 3 15
Phase 2 32
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Apalutamide
Clinical Trial Phase Trials
Not yet recruiting 44
Recruiting 16
Active, not recruiting 2
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Apalutamide

Sponsor Name

Sponsor Name for Apalutamide
Sponsor Trials
Janssen Research & Development, LLC 10
National Cancer Institute (NCI) 9
Janssen Scientific Affairs, LLC 7
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Apalutamide
Sponsor Trials
Industry 51
Other 43
NIH 9
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Johnson and Johnson
Baxter
Medtronic
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.